natgillin/translations-raw huggingface dataset:
A compound according to claim 1 wherein the pathological condition or disease is selected from rheumatoid arthritis, psoriatic arthritis, ankylosing spondilytis, multiple sclerosis, Wegener's granulomatosis, systemic lupus erythematosus, psoriasis and sarcoidosis. 
Spoj prema 1. patentnom zahtjevu, naznačen time da patološko stanje ili bolest može biti reumatoidni artritis, psoriatični artritis, ankilozantni spondilitis, multipla skleroza, Wegenerova granulomatoza, sistemski eritemski lupus, psoriaza i sarkoidoza.
The organic partition was evaporated to yield approximately 5.9g of crude solid. 
Organski dio je bio isparen da bi se dobilo približno 5.9 g sirove krutine.
R is a moiety comprising at least one functional group selected from the group consisting of a double bound, halo, cyano, hydroxyl, sulfonyl, aldehyde, carbonyl, carboxyl, ether, ester, carboxamide, amine, hydrazinyl, ammonium, azide and 5- or 6-membered heterocyclic group with the proviso that R is not allyl; 
Spoj formule I: [image] gdje, R je vrsta koja obuhvaća barem jednu funkcionalnu skupinu izabranu iz grupe koja obuhvaća halo, cijano, hidroksil, sulfonil, aldehid, karbonil, karboksil, eter, ester, karboksamid, amin, hidrazinil, amonij, azid i 5- ili 6-eročlanu heterocikličku skupinu;
The compound or pharmaceutically acceptable salt for use according to claim 3, wherein the disease, health condition or disorder is selected from cardiac interstitial fibrosis, cardiac remodeling and fibrosis. 
Spoj ili farmaceutski prihvatljiva sol za uporabu u skladu sa zahtjevom 3, pri čemu se bolest, zdravstveno stanje ili poremećaj odabire među srčanom intersticijskom fibrozom, srčanom pregradnjom i fibrozom.
A conjugate comprising one or more compounds of any one of claims 1 to 13 covalently bonded to a cell binding agent through the linker comprising a thiol, sulfide or disulfide as a linking group. 
Konjugat, naznačen time što sadrži jedan ili više spojeva u skladu s patentnim zahtjevom 1 ili 2, kovalentno vezanih na sredstvo za vezanje na stanicu preko povezujuće skupine jedne ili više spojnice.
Milk is known to develop undesirable flavour changes when it is exposed to light, in particular sunlight. 
Za mlijeko je poznato da razvija neželjene promjene arome kad je izloženo svjetlu, naročito sunčevom svjetlu.
The present invention further provides a method for making a host cell for production of at least two different Ig-like molecules, the method comprising the step of introducing into said host cell nucleic acid sequences encoding at least a first, a second, a third and a fourth CH3-domain comprising polypeptide chain, wherein at least two of said nucleic acid sequences are provided with means for preferential pairing of said first and second CH3-domain comprising polypeptides and said third and fourth CH3-domain comprising polypeptides, wherein said nucleic acid sequences are introduced consecutively or concomitantly. 
Rekombinantna stanica domaćin koja sadrži sekvence nukleinskih kiselina koje kodiraju najmanje dva različita antitijela, naznačena time što svako od navedena dva antitijela sadrži dvije CH3 domene koje su sposobne da formiraju sučelje, pri čemu navedene sekvence nukleinskih kiselina kodiraju najmanje prvi, drugi, treći i četvrti polipeptidni lanac koji sadrži CH3 domenu, pri čemu navedeni prvi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži lizin (K) ostatak na aminokiselinskom položaju 366 u skladu s EU sustavom numeracije i pri čemu navedeni drugi polipeptidni lanac koji sadrži CH3 domenu sadrži CH3 domenu humanog IgG koji sadrži ostatak asparaginske kiseline (D) na aminokiselinskom položaju 351 u skladu s EU sustavom numeracije.
and R15 are independently hydrogen or a group optionally substituted selected from straight or branched (C1-C8) alkyl, (C3-C8) cycloalkyl, heterocyclyl, aryl and heteroaryl; or a pharmaceutically acceptable salt thereof. 
R14 i R15 su neovisno vodik ili izborno supstituirana skupina, koju se bira između nerazgranatog ili razgranatog (C;-Cg) alkila, (C3-Cg) cikloalkila, heterociklila, arila i heteroarila.
recovering said antibodies, or one of their antigen binding fragments or derivatives, from the culture medium or said cultured cells. 
izolaciju rečenih antitijela ili jednog od njegovih divalentnih fragmenata koji se vežu na c-Met iz medija za kulturu ili rečenih kultiviranih stanica.
and providing a gas flow-line from the off-gas separation section of the melamine production zone to the condensation system, wherein said condensation system is configured for subjecting the vapor from the liquid/gas separation section of the urea plant and the melamine off-gas to combined condensation in indirect heat exchange with the aqueous urea stream. 
linija za protok plina od dijela za odvajanje ispušnih plinova u sklopu zone za proizvodnju melamina do kondenzacijskog sustava, pri čemu je kondenzacijski sustav konfiguriran za obradu pare iz dijela za odvajanje tekućine/plina u sklopu pogona za proizvodnju uree i ispušnih plinova melamina putem kombinirane kondenzacije u neizravnoj izmjeni topline s vodenim mlazom uree.
A compound according to claim 1 for use in the treatment of breast cancer. 
Spoj za uporabu prema zahtjevu 1, naznačen time, da je hiper-proliferativni poremećaj rak dojke.
The pharmaceutical composition according to any preceding claim wherein the pharmaceutically acceptable salt of glycopyrrolate is selected from fluoride, chloride, bromide, iodide, nitrate, sulfate, phosphate, formate, acetate, trifluoroacetate, propionate, butyrate, lactate, citrate, tartrate, malate, maleate, succinate, benzoate, p-chlorobenzoate, diphenyl-acetate or triphenylacetate, o-hydroxybenzoate, p-hydroxybenzoate, 1 -hydroxynaphthalene-2- carboxylate, 3-hydroxynaphthalene-2-carboxylate, methanesulfonate and benzenesulfonate. 
Farmaceutski pripravak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se farmaceutski prihvatljivu sol glikopirolata bira između fluorida, klorida, bromida, jodida, nitrata, sulfata, fosfata, formijata, acetata, trifluoracetata, propionata, butirata, laktata, citrata, tartarata, malata, maleata, sukcinata, benzoata, p-klorbenzoata, difenilacetata ili trifenilacetata, o-hidroksibenzoata, p-hidroksibenzoata, 1-hidroksinaftalen-2-karboksilata, 3-hidroksinaftalen-2-karboksilata, metansulfonata i benzensulfonata.
Use of a composition according to any one of the preceding claims for treatment of type II diabetes or obesity. 
Kompozicija prema patentnom zahtjevu 12, za uporabu u liječenju dijabetesa tipa II 1li pretilosti.
In further another aspect, the present invention provides an afore-described composition for the treatment or alleviation of a skin disease or condition selected from the group consisting of psoriasis, inflammatory skin conditions, onychomycosis, skin cancer, abnormal keratinization induced diseases, skin aging, pustulardermatosis and Cutaneous T Cell Lymphoma (CTCL). 
Rafinirani ekstrakt u skladu s bilo kojim od patentnih zahtjeva 3 do 9, naznačen time što je namijenjen upotrebi u liječenju bolesti ili stanja kojeg se bira iz skupine koju čine psorijaza, upalna stanja kože, onihomikoza, rak kože, bolesti uzrokovane abnormalnim keratiniziranjem, starenje kože, pustozna dermatoza, te CTCL.
a polypeptide encoded by a nucleic acid molecule comprising a nucleotide sequence having at least 80% sequence identity to the nucleic acid sequence of SEQ ID NO:1, 3, or 5, wherein said polypeptide has glyphosate-tolerance activity; and, 
polipeptid koji je kodiran molekulom nukleinske kiseline koja sadrži nukleotidni odsječak koji ima najmanje 80% identitet odsječka odsječku nukleinske kiseline SEQ ID NO: 1, 3 ili 5, pri čemu rečeni polipeptid ima aktivnost tolerancije na glifosat; i
is chloro, bromo or iodo; and each Ra is, independently, C1-6 alkyl; or each Ra, along with the two oxygen atoms and boron atom form a 5- or 6-membered heterocyclic ring; wherein the heterocyclic ring is optionally substituted with 1, 2, 3, or 4 independently selected C1-4 alkyl groups. 
Xu je klor, brom ili jod; i svaki R, je, neovisno, Cig alkil; ili svaki R,, zajedno s dva kisikova atoma i borovim atomom tvori 5- ili 6-člani heterociklički prsten; pri čemu je navedeni heterociklički prsten proizvoljno supstituiran s 1, 2, 3, ili 4 neovisno odabrane skupine C;.4 alkil, poželjno pri čemu spoj s formulom IIIb ima formulu IIIb-1:
In the case of work underlying each Figure, the compound was employed in the form of its hydrochloride salt. 
Dimer buprenorfina iz 1. patentnog zahtjeva, gdje spoj dolazi u obliku farmaceutski prihvatljive soli.
A compound, pharmaceutically acceptable salt or pharmaceutical composition for use according to claim 11, wherein the FXR mediated condition is selected from the group consisting of: a chronic intrahepatic or some form of extrahepatic cholestatic condition; 
Spoj, farmaceutski prihvatljiva sol ili farmaceutski sastav za upotrebu prema zahtjevu 11, pri čemu je FXR posredovano stanje izabran iz grupe koja obuhvaća: kronični intrahepatični ili neki oblik ekstrahepatičnog kolestatskog stanja;
KOH pellets (0.300 g, 5.35 mmol) are added and reflux is continued for 1 hour. 
Dodaju se pilule KOH (0,300 g, 5,35 mmolova) 1 refluktiranje se nastavi još 1 sat.
The invention can be modified in many ways. 
Izum se može modificirati na mnogo načina.
Anhydrous MgC12 (16.2 g, 0.17 mol) dissolved in deionized water (625 ml) was added dropwise under vigorous stirring to a solution of omeprazole sodium salt (125 g, 0.340 mol) in deionized water (1560 ml) and then the stirring was continued for 1h at room temperature. 
Anhidrirani MgCL (16,2 g, 0,17 mola) otopljen je u deioniziranoj vodi (625 ml) dodan je ukapavanjem uz snažno miješanje u otopinu omeprazol natrijeve soli (125, 0,340 mola) u deioniziranoj vodi (1560 ml) i tada je miješanje nastavljeno 1 sat na sobnoj tempcraturi.
A GLA compound according to item 4, wherein x is 11, and the GLA compound has the following structure (IV): 
GLA spoj u skladu s patentnim zahtjevom 3, naznačen time što je x 11, a GLA spoj ima sljedeću strukturu (IV):
a smokeable material heating chamber, defined by the first heating cylinder and the second heating cylinder, configured to receive smokable material, wherein the first heating cylinder and the second heating cylinder are configured to be activated sequentially to independently heat the first region of the smokeable material and the second region of smokeable material. 
Uređaj prema zahtjevu 1 ili 2, naznačen time da grijač sadrži mnoštvo područja za zagrijavanje (10) koja obuhvaćaju prvo područje zagrijavanja koje je postavljeno da grije prvo područje materijala za pušenje i drugo područje zagrijavanja koje je postavljeno da istovremeno zagrijava drugo područje materijala za pušenje.
A method to measure the inhibition of serotonin reuptake in a mammal comprising administering to the mammal a serotonin transporter-inhibiting amount of a compound of formula: where a is 0, 1, 2, 3, or 4; each R1 is independently halo or trifluoromethyl; R3 is hydrogen, halo, or —C1-6alkyl; R4, R5, and R6 are independently hydrogen or halo; or a pharmaceutically acceptable salt thereof. 
Spoj Formule 1: či ili njegova sol, naznačen time da je: L bromo, jodo, ili-OS(O>)-R, gdje je R-C,alkil ili fenil, a fenil je po izboru supstituiran s -C,valkil, halo ili nitro; a je 0, 1, 2, 3, ili 4, svaki R' je neovisno halogen ili trifluorometil, a P je amino-zaštitna skupina odabrana iz t-butoksikarbonil, tritil, benziloksikarbonil, 9-fluorenilmetoksikarbonil, formil, trimetilsilil 1 t-butildimetilsilil.
is the length of another pair of opposite sides of said rectangle; and 
L, je dužina drugog para elemenata okvira (Ho, Hy); 1
reacting the compound of the Formula IX with a compound of the Formula II: in the presence of a suitable base to provide a compound of the Formula X or a salt thereof; 
2-N G-0-$ CH, lI u prisutnosti pogodne baze sa svrhom dobivanja spoja sa formulom X ili njegove soli;
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 7 or a physiologically acceptable salt thereof, and a physiologically acceptable carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1 do 9 ili njegovu farmaceutski prihvatljivu sol te fiziološki prihvatljiv nosač.
The coating material as recited in claim 1, wherein the filler is selected from the group consisting of a carbonate, a sulfate, a silicate, a silicic acid, and an oxide. 
Obložni materijal prema jednom od prethodnih zahtjeva, naznačen time, da su punila odabrana iz skupine koju čine karbonati, sulfati, silikati, silikoni i oksidi.
Thus a decoration or a surface relief may be visible from both sides through the transparent material. 
Na taj način može biti dekoracija ili površinski reljef vidljiv s obje strane kroz prozirni materijal.
A is phenyl which may be substituted by X, benzodioxolanyl which may be substituted by X, or benzodioxanyl which may be substituted by X; 
A jefenil koji se može supstituirati s X, benzodioksolanil koji se može supstituirati s X; ili benzodioksanil koji se može supstituirati s X;
A process according to claims 1 to 4 wherein step b/m is carried out by reacting a compound of formula IIa or IIb with 2-bromo-4-fluorophenol in the presence of a phosphine and an aza compound under Mitsunobu conditions to give a compound of formula IIIa or IIIb in the form of diastereomeric mixture. 
Postupak prema zahtjevima 1 do 4, naznačen time da se koraci b/m provode reakcijom smjese formule Ila ili IIb sa 2-bromo-4-fluorofenolom u prisutnosti fosfina i aza spoja pod uvjetima Mitsunobu, da bi se dobio spoj formule IIIa i NIb u obliku dijasteromerne smjese.
Very good results are achieved with metal-coated spherical beads having a dry bulk resistivity of about 0.001 Ohms/cm. 
Vrlo dobri rezultati se dobivaju s metalom premazanim kuglastim zracima s električnim otporom u suhom nasipnom volumenu od oko 0,001 Ohm-cm.
Method according to one of the preceding claims, characterised in that the lignin-containing fibre according to b) 
Metoda prema nekom od gore navedenih zahtjeva, naznačena time da je vlakno sa ligninom sukladno b)
mixing the conjugate with an S. aureus type 8 capsular polysaccharide conjugated to a carrier molecule. 
miješanje konjugata s polisaharidom kapsule bakterije S. aureus tip 8 konjugiran s molekulom nosača.
The method of claim 1, wherein tipifarnib is administered on days 1-7 and 15-21 of a 28-day treatment cycle. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu je tipifarmib primjenjivan 1-7. i 15-21. dana 28-dnevnog ciklusa liječenja.
a sequence having at least 90% identity with a sequence selected from the group consisting of SEQ ID Nos. 1 -39, 42, 45, and 47-53; 
(b) sekvencu koja obuhvaća barem 90% identiteta sekvence od SEQ ID NO:42 i sadrži jedno ili više mjesta spajanja faktora transkripcije; ili
is selected from the group consisting of hydrogen; oxo; hydroxyl; C1-8 alkyl; C1-8alkoxy; C3-6cycloalkyl; C3-6 cycloalkoxy; and R4 is hydrogen; hydroxyl; alkoxy; C1-8alkyl substituted with 1-3 members of the group consisting of C1-8 alkyl, hydroxyl, cyano, nitro and dialkylamino; 
KP) HR P20090387 TI R, je vodik; hidroksil; alkoksil; C,.galkil supstituiran s 1-3 člana skupine koja se sastoji od C,.s alkila, hidroksila, cijano, nitro i dialkilamino;
enabling the therapeutic cells to access the damaged central nervous system by bypassing the blood-brain barrier. The method of claim 1, further comprising administering the at least one therapeutic cell to a tissue innervated by the olfactory nerve, wherein the at least one therapeutic cell bypasses the blood-brain barrier to access the damaged central nervous system; and 
Terapijske stanice namijenjene upotrebi u skladu s patentnim zahtjevom 1, naznačene time što se navedeno liječenje dodatno sastoji u primjeni terapijskih stanica u tkivo inervirano njušnim živcem, gdje najmanje jedna terapijska stanica zaobilazi krvno-moždanu barijeru kako bi dospijela u oštećeni središnji Živčani sustav; i minimaliziranju sistemskog unosa terapijskih stanica izvan središnjog živčanog sustava.
reacting an intermediate of formula (II) with a suitable acid in the presence of a suitable solvent, wherein W1 represents a suitable leaving group and wherein R1, R3 to R7, p, q and X are defined as in claim 1; 
HR P20090673 T1 pri čemu W predstavlja pogodnu odlaznu skupinu, pri čemu su R' do R', p i q kako je definirano u patentnom zahtjevu 1; e) reakciju intermedijera formule (II) sa podesnom kiselinom u prisutnosti pogodnog otapala, 1
a fourth step, which consists in disengaging the sinkers (33) from the manufacture so that said manufacture, due to the upward thrust, moves so that the loops of its last row of knitting (80) are in the upper heads (9a) of the needles (8); 
- > četvrti korak, koji se sastoji od odvajanja platina (33) od proizvoda te se navedeni proizvod, zbog potiskivanja naviše, pomiče tako da su petlje zadnjeg reda pletiva (80) u gornjim glavama (94) igala (8);
Number of experiments 
Broj međunarodne objave:
The composition of claim 1, wherein the dihydroazole compound of formula (I) is selected from the following: Compound No. 
Veterinarski ili agrikulturni sastav prema zahtjevu 1, naznačen time, da je spoj dihidroazola formule (I) odabran od sljedećih:
A smoke or fire barrier as claimed in any preceding claim, further including a release mechanism (38,39,40) for normally holding the movable side guide (15,115) securely in a fire/smoke retaining position against the side of the pedestrian way. 
Dimna ili požarna prepreka u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time, da sadržava i mehanizam za oslobađanje (38, 39, 40) za normalno pridržavanje pomične bočne vodilice (15, 115) na siguran način u položaju za zadržavanje požara / dima na strani prolaza za osobe.
In an embodiment the concentration of Zn2+ in the cerebrospinal fluid is less than 1.5, 1, 0.75, 0.5, 0.25 or 0.1 uM or less than 100, 75, 50, 40, 25, or 10 ug/L. In an embodiment, the concentration of Mn2+ in the cerebrospinal fluid is less than 2.5, 2, 1.5, 1 or 0.5 ug/L or less than 50, 25, 10 or 5 nM. In an embodiment of the invention, the human patient has decreased level(s) of Zn2+ and/or Mn2+ as measured by broncheal lavage and/or blood test. 
Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u moždanim ovojnicama, a koncentracija Zn"* u cerebrospinalnoj tekućini je manja od 1,5, 1, 0,75, 0,5, 0,25 ili 0,1 uM ili manja od 100, 75, 50, 25 ili 10 ug/1. Imunogeni pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-3 ili 11, naznačen time što do infekcije bakterijom Streptococcus pneumoniae dolazi u moždanim ovojnicama, a koncentracija Mn"* u cerebrospinalnoj tekućini je manja od 2,5, 2, 1,5, 1 ili 0,5 ug/1 ili manja od 50, 25, 10 ili SnM.
comprising the following steps: providing a compound according to formula (14), or salt thereof, 
p postup IJU SPOJ skladu sa sljedećom formulom (14) ili njegove soli: 1
is a group of Formula (A): 
Rs je skupina Formule (A): gdje:
expressing a SAP polypeptide in a CHO cell; and ii) isolating the SAP polypeptide from the cell. 
ekspresija SAP polipeptida u CHO stanici; i ii) izolaciju SAP polipeptida iz stanice.
a moveable member that engages a flexible length of aspiration line, a position of the moveable member with respect to the flexible length of aspiration line determining a leakage that decreases vacuum pressure in the rigid length of aspiration line. 
Ručni aparat prema zahtjevu 1, naznačen time, da se položaj osovine (220) može podešavati u odnosu na fleksibilnu cijev, u svrhu određivanja curenja koje smanjuje tlak vakuuma u krutoj duljini usisnog voda.
An antibody drug conjugate comprising an anti-191P4D12 antibody or antigen binding fragment thereof comprising a heavy chain variable region consisting of the amino acid sequence of the heavy chain variable region of an antibody produced by a hybridoma deposited under American Type Culture Collection (ATCC) Accession No. 
Konjugat antitijela i lijeka koji sadrži anti-191P4D12 antitijelo ili fragment istog koji veže antigen, koji sadrži varijabilnu regiju teškog lanca koja se sastoji od sekvence amino kiseline varijabilne regije teškog lanca antitijela proizvedenog hibridomom koje je pohranjeno u Američkoj kolekciji tipova kulture (American Type Culture Collection - ATCC) Acesijski Br.
The formulation according to the present invention can further contain a surfactant. 
Formulacija prema zahtjevu 1 naznačena time da nadalje sadrži histidinsko pufersko sredstvo.
Definitions “Alkyl” means a monovalent group derived from a saturated or unsaturated (but not aromatically unsaturated), hydrocarbon that may be linear, branched, or cyclic by removal of one hydrogen atom from a carbon atom, such as methyl, ethyl, propyl, 1-propenyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, cyclopentyl, cyclopenten-1-yl, cyclopropylmethyl, cyclohexyl, and cyclohexylmethyl. 
«Alkil» znači monovalentnu skupinu izvedenu iz zasićenog ili nezasićenog (ali ne aromatskog nezasićenog) Ci.19, poželjno Cis, ugljikovodika koji može biti ravan, razgranat ili ciklički, odstranjivanjem jednog atoma vodika sa ugljikovog atoma, kao što je mtil, etil, propil, 1-propenil, izopropil, butil, izobutil, sek-butil, terc-butil, pentil, heksil, ciklopentil, ciklopenten-1-il, ciklopropilmetil, cikloheksil i cikloheksilme1l.
moving the rotating container through the vacuum chamber from the input end (30) to a discharge end (34) thereof while applying microwave radiation to dehydrate the organic material; and 
(d) pokretanja posude koja rotira kroz vakuumsku komoru od ulaznog kraja (30) do kraja (34) za pražnjenje iste dok se primjenjuje mikrovalno zračenje da se dehidrira organski materijal; i
Next, Formula 42 was converted to a compound of Formula 43 according to the following reaction: A quantity of Formula 42 (3.0g, 2.829mmol) was weighed into a 100mL flask. 
Nakon toga je formula 42 konvertirana u spoj formule 43 prema sljedećoj reakciji: 9_Q4 ose, PE Em
coupling a compound of formula (II) with a compound of formula (IV) in a suitable solvent, in the presence of a coupling agent, and optionally in the presence of an activating agent of the coupling agent; or 
(IV) u pogodnom otapalu, u prisutnosti kondenzacijskog sredstva, te izborno u prisutnosti aktivacijskog sredstva za kondenzacijsko sredstvo; ili a2) prevođenja spoja formule (II) u spoj formule (III) uz aktivacijsko sredstvo, te kondenziranja navedenog spoja formule (III)
The compound of claim 10, wherein the disease or condition which can be influenced by inhibiting the enzyme 11B-hydroxysteroid dehydrogenase (HSD) 1 is a metabolic disorder. 
Spoj prema zahtjevu 10, naznačen time da je bolest ili stanje na koje se može utjecati inhibiranjem enzima 11B-hidroksisteroid dehidrogenaze (HSD) 1 metabolički poremećaj.
The peptide according to any of claims 1 to 3 which is fused to the N-terminal amino acids of the HLA-DR antigen-associated invariant chain (Ii). 
Peptid u skladu s patentnim zahtjevom 1 ili 2, koji je fuzioniran u N-terminalne aminokiseline HLA-DR invarijantnog lanca vezanog za antigene (Ii).
The extended release dosage form of item 97, wherein the opioid analgesic is selected from the group of codeine, morphine, oxycodone, hydrocodone, hydromorphone, or oxymorphone or pharmaceutically acceptable salts, hydrates and solvates thereof, mixtures of any of the foregoing. 
Oblik doziranja sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 22, naznačen time da je opioidni analgetik odabran iz skupine koja sadrži kodein, morfin, oksikodon, hidrokodon, hidromorfon, ili oksimorfon ili njihove farmaceutski prihvatljive soli, hidrati i solvati, te bilo koje smjese prethodno navedenih analgetika.
A reconstituted surfactant according to claim 1, wherein said lipid carrier comprises a mixture of phospholipids. 
Rekonstituirani surfakant prema patentnom zahtjevu 1, naznačen time da polipeptidni analog prirodnog surfakanta proteina SP-C jest